Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.65 |
| ▸ | PPARD | Q03181 | 8/20 | 0.65 |
| ▸ | PPARA | Q07869 | 7/20 | 0.65 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041634 | 0.87 | PPARG (0.50) | PPARGPPARDPPARALDHALTA4H | |
| SCHEMBL28512690 | 0.86 | PPARG (0.67) | PPARGPPARDPPARAPTPRBACACB | |
| SCHEMBL6704879 | 0.86 | PPARG (0.71) | PPARGPPARDPPARAPTPRBLDHA | |
| SCHEMBL20395690 | 0.86 | PPARG (0.67) | PPARGPPARDPPARAPTPRBLDHA | |
| SCHEMBL6382746 | 0.86 | PPARG (0.67) | PPARGPPARDPPARAPTPRBLDHA | |
| SCHEMBL6696075 | 0.85 | PPARG (0.66) | PPARGPPARDPPARAPTPRBLDHA | |
| SCHEMBL7018529 | 0.84 | LDHA (0.59) | PPARGPPARDPPARALDHA | |
| SCHEMBL5892206 | 0.83 | PPARG (0.54) | PPARGPPARDPPARALTA4H | |
| SCHEMBL6383472 | 0.83 | PPARG (0.60) | PPARGPPARDPPARAPTPRB | |
| SCHEMBL20395698 | 0.83 | PPARG (0.62) | PPARGPPARDPPARAPTPRBLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1211374-C | Heterocylic derivative, its preparation method and medicine composition containing them | SEUVIR LABVORATORY (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
| CN-1396915-A | Novel heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2003-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | PPARG 414/4885PPARD 273/4885PPARA 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.